Sign in or create an account to add this stock to your watchlist.
About Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ESPR
CUSIPN/A
Phone734-887-3903
Debt
Debt-to-Equity RatioN/A
Current Ratio6.70
Quick Ratio6.70
Price-To-Earnings
Trailing P/E Ratio-5.85
Forward P/E Ratio-6.75
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.99 per share
Price / Book5.07
Profitability
EPS (Most Recent Fiscal Year)($6.98)
Net Income$-166,980,000.00
Net MarginsN/A
Return on Equity-77.47%
Return on Assets-67.65%
Miscellaneous
Employees57
Outstanding Shares26,790,000
Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions
What is Esperion Therapeutics' stock symbol?
Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."
How were Esperion Therapeutics' earnings last quarter?
Esperion Therapeutics Inc (NASDAQ:ESPR) issued its quarterly earnings data on Wednesday, May, 2nd. The biopharmaceutical company reported ($1.73) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by $0.17. During the same period in the previous year, the business posted ($1.80) EPS. View Esperion Therapeutics' Earnings History.
When is Esperion Therapeutics' next earnings date?
What price target have analysts set for ESPR?
13 brokers have issued 1 year target prices for Esperion Therapeutics' stock. Their predictions range from $41.00 to $153.00. On average, they anticipate Esperion Therapeutics' share price to reach $89.0769 in the next year. View Analyst Ratings for Esperion Therapeutics.
What are Wall Street analysts saying about Esperion Therapeutics stock?
Here are some recent quotes from research analysts about Esperion Therapeutics stock:
- 1. Chardan Capital analysts commented, "We see numerous reasons for our new positive bias, including: A path forward for both BA and a BA+ezetimibe (BA+eze) fixed dose combo (FDC) has been confirmed by the FDA. A definition of statin intolerance has also been agreed on by the FDA. KOLs (e.g. Dr. Nissen) support the need for therapies for patients who are (or believe themselves to be) statin intolerant and refuse statins. CANTOS suggests BA’s high-sensitivity C-reactive protein (hsCRP) lowering effect is highly relevant for CV event reduction and outcomes. Newly-disclosed integrated phase II results suggest sound BA safety. A larger market opportunity results from a pivotal BA phase III design that includes patients “on any statin dose.” Limited use of PCSK9 inhibitors, due to pricing, opens an opportunity. Merck’s (unrated) decision not to file anacetrapib for approval further confirms oral CETP inhibitors as uninteresting assets or competitors." (12/5/2017)
- 2. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (8/23/2017)
Who are some of Esperion Therapeutics' key competitors?
Some companies that are related to Esperion Therapeutics include Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Portola Pharmaceuticals (PTLA), Ironwood Pharmaceuticals (IRWD), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT) and The Medicines (MDCO).
Who are Esperion Therapeutics' key executives?
Esperion Therapeutics' management team includes the folowing people:
- Mr. Timothy M. Mayleben, CEO, Pres & Director (Age 57)
- Dr. Narendra D. Lalwani Ph.D., FAHA, DABT, MBA, Chief Operating Officer and Exec. VP of R&D (Age 65)
- Dr. Mary P. McGowan M.D., Chief Medical Officer (Age 58)
- Mr. Richard B. Bartram, CFO, Principal Accounting Officer & Corp. Sec.
- Ms. Marianne Andreach, Sr. VP of Product Planning
Has Esperion Therapeutics been receiving favorable news coverage?
Media headlines about ESPR stock have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Esperion Therapeutics earned a coverage optimism score of 0.11 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.25 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Esperion Therapeutics' major shareholders?
Esperion Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BB Biotech AG (9.01%), BlackRock Inc. (5.56%), Pinnacle Associates Ltd. (2.36%), Wasatch Advisors Inc. (2.21%), Northern Trust Corp (2.16%) and Amundi Pioneer Asset Management Inc. (1.10%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani, Nicole Vitullo, Roger S Newton and Target N V Biotech. View Institutional Ownership Trends for Esperion Therapeutics.
Which institutional investors are selling Esperion Therapeutics stock?
ESPR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Lord Abbett & CO. LLC, Wasatch Advisors Inc., Candriam Luxembourg S.C.A., New York State Common Retirement Fund, Pinnacle Associates Ltd., BlackRock Inc. and Guggenheim Capital LLC. Company insiders that have sold Esperion Therapeutics company stock in the last year include Nicole Vitullo and Roger S Newton. View Insider Buying and Selling for Esperion Therapeutics.
Which institutional investors are buying Esperion Therapeutics stock?
ESPR stock was acquired by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Bellevue Group AG, JPMorgan Chase & Co., SG Americas Securities LLC, Amundi Pioneer Asset Management Inc., A.R.T. Advisors LLC, BB Biotech AG and Spark Investment Management LLC. Company insiders that have bought Esperion Therapeutics stock in the last two years include Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Target N V Biotech. View Insider Buying and Selling for Esperion Therapeutics.
How do I buy shares of Esperion Therapeutics?
Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Esperion Therapeutics' stock price today?
One share of ESPR stock can currently be purchased for approximately $38.99.
How big of a company is Esperion Therapeutics?
Esperion Therapeutics has a market capitalization of $1.01 billion. The biopharmaceutical company earns $-166,980,000.00 in net income (profit) each year or ($6.98) on an earnings per share basis. Esperion Therapeutics employs 57 workers across the globe.
How can I contact Esperion Therapeutics?
Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]
MarketBeat Community Rating for Esperion Therapeutics (ESPR)
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe ESPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Esperion Therapeutics (NASDAQ:ESPR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
13 Wall Street analysts have issued ratings and price targets for Esperion Therapeutics in the last 12 months. Their average twelve-month price target is $89.0769, suggesting that the stock has a possible upside of 119.94%. The high price target for ESPR is $153.00 and the low price target for ESPR is $41.00. There are currently 2 sell ratings, 2 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.62 | 2.77 | 2.69 | 2.67 |
| Ratings Breakdown: | 2 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $89.0769 | $96.3077 | $79.5385 | $58.9167 |
| Price Target Upside: | 119.94% upside | 28.96% upside | 4.95% upside | 21.40% upside |
Esperion Therapeutics (NASDAQ:ESPR) Consensus Price Target History
Esperion Therapeutics (NASDAQ:ESPR) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Esperion Therapeutics (NASDAQ:ESPR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Esperion Therapeutics (NASDAQ ESPR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.50%
Institutional Ownership Percentage: 98.35%
Esperion Therapeutics (NASDAQ ESPR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/21/2018 | Target N V Biotech | Major Shareholder | Buy | 130,000 | $40.11 | $5,214,300.00 | 2,872,964 |  |
| 5/18/2018 | Target N V Biotech | Major Shareholder | Buy | 50,000 | $42.24 | $2,112,000.00 | 2,872,964 | |
| 3/29/2018 | Roger S Newton | Director | Sell | 25,000 | $72.37 | $1,809,250.00 | 639,682 | |
| 1/25/2018 | Nicole Vitullo | Director | Sell | 11,674 | $71.79 | $838,076.46 | 3,177 | |
| 12/6/2017 | Nicole Vitullo | Director | Sell | 9,326 | $53.85 | $502,205.10 | 2,472 | |
| 3/22/2017 | Dov A Md Goldstein | Director | Sell | 800,000 | $41.66 | $33,328,000.00 | | |
| 3/21/2017 | Gilbert S Omenn | Director | Buy | 1,000 | $42.26 | $42,260.00 | 10,000 | |
| 11/1/2016 | Narendra D Lalwani | COO | Buy | 5,000 | $9.93 | $49,650.00 | 5,000 | |
| 7/6/2016 | Mark E Mcgovern | Director | Buy | 5,000 | $10.00 | $50,000.00 | 600 | |
| 5/4/2016 | Timothy M Mayleben | CEO | Buy | 7,000 | $14.85 | $103,950.00 | 41,614 | |
| 3/1/2016 | Gilbert S Omenn | Director | Buy | 5,000 | $15.28 | $76,400.00 | 10,000 | |
| 1/27/2016 | Timothy M Mayleben | CEO | Buy | 3,600 | $15.88 | $57,168.00 | 34,614 | |
| 1/15/2016 | Timothy M Mayleben | CEO | Buy | 7,200 | $14.08 | $101,376.00 | 31,014 | |
| 4/24/2015 | Dov A Md Goldstein | Director | Sell | 217,469 | $108.22 | $23,534,495.18 | | |
| 11/18/2014 | Patrick G Enright | Director | Sell | 487,130 | $32.78 | $15,968,121.40 | | |
| 10/21/2014 | Parters Vii L P Domain | Major Shareholder | Buy | 500,000 | $20.00 | $10,000,000.00 | | |
| 10/7/2014 | Longitude Capital Partners, Ll | Major Shareholder | Sell | 11,927 | $30.04 | $358,287.08 | | |
| 7/1/2013 | Brian H Dovey | Major Shareholder | Buy | 285,714 | $14.00 | $3,999,996.00 | | |
| 7/1/2013 | Daniel Janney | Director | Buy | 235,714 | $14.00 | $3,299,996.00 | | |
| 7/1/2013 | Roger S Newton | Chairman | Buy | 42,346 | $14.00 | $592,844.00 | | |
| 7/1/2013 | Timothy M Mayleben | CEO | Buy | 5,000 | $14.00 | $70,000.00 | | |
(Data available from 1/1/2013 forward)
Esperion Therapeutics (NASDAQ ESPR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Primary Endpoint
finance.yahoo.com - May 23 at 8:37 AM |
| ESPR INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Esperion Therapeutics, Inc. and a Lead Plaintiff Deadline of July 6, 2018
finance.yahoo.com - May 22 at 4:54 PM |
 | Target N. V. Biotech Acquires 50,000 Shares of Esperion Therapeutics Inc (ESPR) Stock
www.americanbankingnews.com - May 22 at 4:18 PM |
| Insider Buying: Esperion Therapeutics Inc (ESPR) Major Shareholder Buys 130,000 Shares of Stock
www.americanbankingnews.com - May 22 at 4:18 PM |
| Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
finance.yahoo.com - May 22 at 8:40 AM |
| Esperion Therapeutics (ESPR) Expected to Post Earnings of -$1.76 Per Share
www.americanbankingnews.com - May 19 at 1:23 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – ESPR
finance.yahoo.com - May 19 at 8:37 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018
finance.yahoo.com - May 17 at 5:41 PM |
| ESPR REMINDER: Pawar Law Reminds Investors of Important July 6, 2018 Lead Plaintiff Deadline in Class Action– ESPR
finance.yahoo.com - May 17 at 5:41 PM |
 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018 – ESPR
feeds.benzinga.com - May 16 at 7:27 PM |
 | ESPR ALERT: Rosen Law Firm Reminds Esperion Therapeutics, Inc. Investors of Important July 6 Deadline in Class Action
www.bizjournals.com - May 16 at 5:11 PM |
 | Esperion Therapeutics (ESPR) Presents At Bank Of America Merrill Lynch 2018 Healthcare Conference - Slideshow
seekingalpha.com - May 16 at 5:11 PM |
| Esperion Therapeutics' (ESPR) Buy Rating Reiterated at UBS
www.americanbankingnews.com - May 16 at 1:49 PM |
| IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - May 16 at 8:54 AM |
| The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Esperion Therapeutics, Inc. (ESPR)
finance.yahoo.com - May 15 at 5:27 PM |
| DEADLINE ALERT: Shareholder Class Action Lawsuit Filed Against Esperion Therapeutics, Inc. – ESPR
finance.yahoo.com - May 15 at 9:01 AM |
 | Buyer of Esperion Therapeutics (ESPR) on Weakness - Needham & Company
www.streetinsider.com - May 14 at 5:03 PM |
| The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Esperion Therapeutics, Inc. (ESPR)
finance.yahoo.com - May 14 at 5:03 PM |
 | ESPR INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible ...
www.businesswire.com - May 12 at 9:05 AM |
| INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - May 12 at 9:04 AM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ESPR
finance.yahoo.com - May 12 at 9:04 AM |
| Esperion Therapeutics (ESPR) Presents At 43rd Annual Deutsche Bank Healthcare Conference - Slideshow
seekingalpha.com - May 10 at 5:26 PM |
| ESPR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of ...
www.businesswire.com - May 10 at 5:26 PM |
| Important Deadline Notice for Esperion Therapeutics, Inc. Shareholders - ESPR
finance.yahoo.com - May 10 at 5:26 PM |
| ESPR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc.
finance.yahoo.com - May 10 at 5:26 PM |
| Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc.
finance.yahoo.com - May 10 at 5:26 PM |
| SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. - ESPR
finance.yahoo.com - May 10 at 5:26 PM |
| Kessler Topaz Meltzer & Check, LLP Announces Investor Class Action Filed Against Esperion Therapeutics, Inc. - ESPR
finance.yahoo.com - May 10 at 5:26 PM |
 | Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare Conference
globenewswire.com - May 10 at 8:52 AM |
| Pomerantz Law Firm Announces the Filing of a Class Action against Esperion Therapeutics, Inc. and Certain Officers – ESPR
globenewswire.com - May 9 at 5:09 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc.
finance.yahoo.com - May 9 at 5:09 PM |
| SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - May 9 at 5:09 PM |
| Deadline Alert for Esperion Therapeutics, Inc. Shareholders in Class Action Lawsuit - ESPR
finance.yahoo.com - May 9 at 8:48 AM |
| ESPERION INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Esperion Therapeutics, Inc. To Contact The Firm
finance.yahoo.com - May 9 at 8:48 AM |
| EQUITY ALERT: Rosen Law Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc ...
www.businesswire.com - May 8 at 5:11 PM |
| Pomerantz Law Firm Announces the Filing of a Class Action against Esperion Therapeutics, Inc. and Certain Officers ...
www.globenewswire.com - May 8 at 5:11 PM |
| Bragar Eagel & Squire, PC Announces That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc ...
www.businesswire.com - May 8 at 5:11 PM |
| Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc. (ESPR) and Encourages Investors to Contact the Firm
finance.yahoo.com - May 8 at 5:11 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc.
finance.yahoo.com - May 8 at 5:11 PM |
| IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - May 8 at 5:11 PM |
| Is Esperion Therapeutics Inc. a Buy on the Dip?
finance.yahoo.com - May 8 at 8:44 AM |
| Esperion Therapeutics (ESPR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 7 at 3:37 PM |
| Q2 2018 EPS Estimates for Esperion Therapeutics (ESPR) Lowered by Jefferies Group
www.americanbankingnews.com - May 7 at 2:26 AM |
| JPMorgan Downgrades Esperion Therapeutics (ESPR) to Underweight Citing an Extended Road to Recovery
www.streetinsider.com - May 5 at 5:11 PM |
| Analyzing the Research Pipeline of Esperion Therapeutics
finance.yahoo.com - May 5 at 8:54 AM |
| Analyzing the Financial Performance of Esperion Therapeutics
finance.yahoo.com - May 5 at 8:54 AM |
| Esperion Therapeutics (ESPR) PT Lowered to $73.00
www.americanbankingnews.com - May 5 at 2:59 AM |
| Here's Why Esperion Therapeutics Inc. Stock Is Bouncing Back Today
finance.yahoo.com - May 4 at 5:05 PM |
| Esperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - May 4 at 5:05 PM |
 | Here's Why Esperion Therapeutics Inc. Stock Is Bouncing Back Today
www.fool.com - May 4 at 1:17 PM |
Esperion Therapeutics (NASDAQ:ESPR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Esperion Therapeutics (NASDAQ:ESPR) Income Statement, Balance Sheet and Cash Flow Statement
Esperion Therapeutics (NASDAQ ESPR) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
